Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Remdesivir plus tocilizumab versus remdesivir plus placebo for severe COVID-19 pneumonia
2020-002275-34Phase 3Completed
- Sponsor
- Roche
- Start
- Nov 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in coronavirus pneumonia and coronavirus disease 2019 (COVID-19) comparing Remdesivir + tocilizumab with Remdesivir + placebo (2 arms). Primary endpoint: Time from randomization to hospital discharge or ready for discharge. Started Nov 2020; status: completed.
02
Drugs
tocilizumabremdesivir
03
Conditions
coronavirus pneumoniacoronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on 2020-002275-34.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-002275-34.